Preclinical evidence finds no stable CBD dose-response for fear
Can a generalizable dose-effect relationship be inferred for cannabidiol? Evidence from the preclinical literature.
AI Summary
This study asked whether preclinical research supports a consistent relationship between CBD dose and changes in anxiety- and fear-related behavior. The authors used regression analyses to examine effect sizes from 312 experiments in mice and rats, considering anxiety and conditioned-fear outcomes separately and together, and comparing raw with allometrically adjusted doses. This was an analysis of animal studies, not a human clinical trial.
Intermediate systemic doses were more often linked to larger reductions in aversive behavior, but that pattern did not hold consistently across species or behavioral domains. Some analyses suggested nonlinear relationships, while pooled, allometrically adjusted analyses favored linear models; overall, the literature did not support a stable, generalizable CBD dose-effect relationship. The findings may reflect substantial differences in study methods and CBD’s pharmacological complexity. Because this abstract-based summary describes a synthesis of varied preclinical experiments, it cannot establish a dose response in people or determine an effective dose; the authors call for more controlled, balanced factorial studies.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
Randomized trial finds CBD did not reduce severe behavioral problems
Post hoc TSC analysis links caregiver-perceived improvement to seizure…
Repeated high-dose CBD in young rats was followed by mixed social changes and…
Explore More Research
Stay informed about the latest cannabis science.